An experimental treatment for Type 2 diabetes, which aims to allow patients to manage their disease without taking medication, has entered its third round of clinical trials at St Joseph's Healthcare ...
The Food and Drug Administration has granted de novo classification to a continuous glucose monitor made by Biolinq for ...
TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback